{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:06:04Z","timestamp":1779527164993,"version":"3.53.1"},"reference-count":132,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Surgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recently reported, although a comprehensive assessment of the overall evidence is lacking. A systematic scoping review was conducted to assess the early evidence on cilostazol administration in patients with MMD. The inclusion criteria encompassed original human studies primarily focused on cilostazol\u2019s safety, efficacy, or utilization in managing MMD patients. A search of the PubMed database was conducted in June 2023, yielding 5 peer-reviewed publications that satisfied the inclusion criteria and were subjected to narrative synthesis. Risk of bias assessment was not applicable due to the scoping nature of this review. East Asian studies demonstrate increasing rates of cilostazol prescriptions for patients with MMD. In a large population-based study, cilostazol was compared to other antiplatelet medications and yielded the largest decrease in mortality among patients with newly diagnosed MMD. Other studies reported significant improvements in cerebral blood flow and cognitive function, which were deemed to be independent of one another. There are limited data on the safety profile of cilostazol in the MMD population, although the evidence derived from various studies performed in the general stroke population can likely provide insights into its potential utility in MMD patients. Cilostazol targets several critical pathways involved in the pathophysiology of MMD. The evidence corroborates the potential benefits of cilostazol for the management of MMD, although these findings should be interpreted with caution due to the small number of studies and lack of randomized trials. Subgroups of patients need to be identified who can safely undergo medical management in lieu of revascularization surgery or to improve surgical outcomes. Additional studies are needed to assess the efficacy and safety of cilostazol therapy, especially in Western populations.<\/jats:p>","DOI":"10.3171\/2023.7.focus23327","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T09:30:07Z","timestamp":1696152607000},"page":"E9","source":"Crossref","is-referenced-by-count":8,"title":["Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions"],"prefix":"10.3171","volume":"55","author":[{"given":"Aidin","family":"Abedi","sequence":"first","affiliation":[{"name":"USC Neurorestoration Center and"},{"name":"Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Sizdahkhani","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooseong","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent N.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Rennert","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Russin","sequence":"additional","affiliation":[{"name":"USC Neurorestoration Center and"},{"name":"Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"1","key":"b1","series-title":"J Stroke","first-page":"2","article-title":"Moyamoya disease: epidemiology, clinical features, and diagnosis","volume":"18","author":"Kim JS","year":"2016","unstructured":"Kim JS. Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke. 2016;18(1):2\u201311."},{"issue":"11","key":"b2","series-title":"Int J Clin Exp Med","first-page":"21351","article-title":"Ischemic and hemorrhagic moyamoya disease in adults: CT findings","volume":"8","author":"Xie A","year":"2015","unstructured":"Xie A, Luo L, Ding Y, Li G. Ischemic and hemorrhagic moyamoya disease in adults: CT findings. Int J Clin Exp Med. 2015;8(11):21351\u201321357."},{"issue":"4","key":"b3","series-title":"Neurosurg Clin N Am","first-page":"403","article-title":"Rethinking cerebral bypass surgery","volume":"33","author":"Rennert RC","year":"2022","unstructured":"Rennert RC, Russin JJ. Rethinking cerebral bypass surgery. Neurosurg Clin N Am. 2022;33(4):403\u2013417."},{"issue":"3","key":"b4","series-title":"Int J Stroke","first-page":"246","article-title":"Etiology and pathogenesis of moyamoya disease: an update on disease prevalence","volume":"12","author":"Huang S","year":"2017","unstructured":"Huang S, Guo ZN, Shi M, Yang Y, Rao M. Etiology and pathogenesis of moyamoya disease: an update on disease prevalence. Int J Stroke. 2017;12(3):246\u2013253."},{"key":"b5","series-title":"Primer on Cerebrovascular Diseases","first-page":"561","article-title":"Moyamoya disease and syndrome","author":"Kim JS","year":"2017","unstructured":"Kim JS. Moyamoya disease and syndrome. In: Caplan LR, Biller J, Leary MC,  eds. Primer on Cerebrovascular Diseases. 2nd ed. Academic Press; 2017:561-566."},{"issue":"1","key":"b6","series-title":"J Stroke","first-page":"12","article-title":"The pathophysiology of moyamoya disease: an update","volume":"18","author":"Bang OY","year":"2016","unstructured":"Bang OY, Fujimura M, Kim SK. The pathophysiology of moyamoya disease: an update. J Stroke. 2016;18(1):12\u201320."},{"issue":"71","key":"b7","series-title":"BMJ","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM,  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71):n71."},{"issue":"5","key":"b8","series-title":"Neurol Med Chir (Tokyo)","first-page":"245","article-title":"Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis)","volume":"52","year":"2012","unstructured":"Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52(5):245\u2013266."},{"issue":"5","key":"b9","series-title":"Cerebrovasc Dis","first-page":"455","article-title":"Perfusion-weighted magnetic resonance imaging used in assessing hemodynamics following superficial temporal artery-middle cerebral artery bypass in patients with moyamoya disease","volume":"35","author":"Li Z","year":"2013","unstructured":"Li Z, Zhou P, Xiong Z,  Perfusion-weighted magnetic resonance imaging used in assessing hemodynamics following superficial temporal artery-middle cerebral artery bypass in patients with moyamoya disease. Cerebrovasc Dis. 2013;35(5):455\u2013460."},{"issue":"1","key":"b10","series-title":"Eur Radiol","first-page":"254","article-title":"CT perfusion assessment of moyamoya syndrome before and after direct revascularization (superficial temporal artery to middle cerebral artery bypass)","volume":"26","author":"Chen Y","year":"2016","unstructured":"Chen Y, Xu W, Guo X,  CT perfusion assessment of moyamoya syndrome before and after direct revascularization (superficial temporal artery to middle cerebral artery bypass). Eur Radiol. 2016;26(1):254\u2013261."},{"issue":"12","key":"b11","series-title":"Stroke","first-page":"3572","article-title":"Direct, indirect, and combined extracranial-to-intracranial bypass for adult moyamoya disease: an updated systematic review and meta-analysis","volume":"53","author":"Nguyen VN","year":"2022","unstructured":"Nguyen VN, Motiwala M, Elarjani T,  Direct, indirect, and combined extracranial-to-intracranial bypass for adult moyamoya disease: an updated systematic review and meta-analysis. Stroke. 2022;53(12):3572\u20133582."},{"key":"b12","series-title":"Front Surg","first-page":"966430","article-title":"Surgical techniques and indications for treatment of adult moyamoya disease","volume":"9","author":"Nguyen VN","year":"2022","unstructured":"Nguyen VN, Parikh KA, Motiwala M,  Surgical techniques and indications for treatment of adult moyamoya disease. Front Surg. 2022;9:966430."},{"issue":"5","key":"b13","series-title":"Neurosurg Focus","first-page":"e5","article-title":"Long-term outcome after STA-MCA anastomosis for moyamoya disease","volume":"5","author":"Miyamoto S","year":"1998","unstructured":"Miyamoto S, Akiyama Y, Nagata I,  Long-term outcome after STA-MCA anastomosis for moyamoya disease. Neurosurg Focus. 1998;5(5):e5."},{"issue":"2","key":"b14","series-title":"Neurosurg Focus","first-page":"E15","article-title":"Long-term outcome of superficial temporal artery-middle cerebral artery bypass for patients with moyamoya disease in the US","volume":"24","author":"Mesiwala AH","year":"2008","unstructured":"Mesiwala AH, Sviri G, Fatemi N, Britz GW, Newell DW. Long-term outcome of superficial temporal artery-middle cerebral artery bypass for patients with moyamoya disease in the US. Neurosurg Focus. 2008;24(2):E15."},{"issue":"5","key":"b15","series-title":"Stroke","first-page":"1415","article-title":"Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial","volume":"45","author":"Miyamoto S","year":"2014","unstructured":"Miyamoto S, Yoshimoto T, Hashimoto N,  Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke. 2014;45(5):1415\u20131421."},{"key":"b16","series-title":"World Neurosurg","first-page":"354","article-title":"Meta-analysis of prognosis of different treatments for symptomatic moyamoya disease","volume":"127","author":"Li Q","year":"2019","unstructured":"Li Q, Gao Y, Xin W,  Meta-analysis of prognosis of different treatments for symptomatic moyamoya disease. World Neurosurg. 2019;127:354\u2013361."},{"issue":"3","key":"b17","series-title":"J Neurosurg","first-page":"793","article-title":"Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults","volume":"128","author":"Jeon JP","year":"2018","unstructured":"Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW. Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg. 2018;128(3):793\u2013799."},{"issue":"4","key":"b18","series-title":"Neurosurg Focus","first-page":"E7","article-title":"Surgical management of moyamoya disease: a review","volume":"26","author":"Baaj AA","year":"2009","unstructured":"Baaj AA, Agazzi S, Sayed ZA, Toledo M, Spetzler RF, van Loveren H. Surgical management of moyamoya disease: a review. Neurosurg Focus. 2009;26(4):E7."},{"issue":"3","key":"b19","series-title":"Surg Neurol","first-page":"273","article-title":"Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease","volume":"67","author":"Fujimura M","year":"2007","unstructured":"Fujimura M, Kaneta T, Mugikura S, Shimizu H, Tominaga T. Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol. 2007;67(3):273\u2013282."},{"issue":"10","key":"b20","series-title":"Childs Nerv Syst","first-page":"734","article-title":"How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography","volume":"20","author":"Houkin K","year":"2004","unstructured":"Houkin K, Nakayama N, Kuroda S, Ishikawa T, Nonaka T. How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst. 2004;20(10):734\u2013741."},{"issue":"6","key":"b21","series-title":"Surg Neurol","first-page":"541","article-title":"Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients?","volume":"45","author":"Mizoi K","year":"1996","unstructured":"Mizoi K, Kayama T, Yoshimoto T, Nagamine Y. Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients? Surg Neurol. 1996;45(6):541\u2013549."},{"issue":"suppl 2","key":"b22","series-title":"Clin Neurol Neurosurg","first-page":"S151","article-title":"Moyamoya disease in adults: characteristics of clinical presentation and outcome after encephalo-duro-arterio-synangiosis","volume":"99","author":"Han DH","year":"1997","unstructured":"Han DH, Nam DH, Oh CW. Moyamoya disease in adults: characteristics of clinical presentation and outcome after encephalo-duro-arterio-synangiosis. Clin Neurol Neurosurg. 1997;99(suppl 2):S151\u2013S155."},{"issue":"4","key":"b23","series-title":"Neurosurg Rev","first-page":"1877","article-title":"Limits and pitfalls of indirect revascularization in moyamoya disease and syndrome","volume":"44","author":"Fiaschi P","year":"2021","unstructured":"Fiaschi P, Scala M, Piatelli G,  Limits and pitfalls of indirect revascularization in moyamoya disease and syndrome. Neurosurg Rev. 2021;44(4):1877\u20131887."},{"issue":"10","key":"b24","series-title":"Stroke","first-page":"3025","article-title":"Long-term outcomes after combined revascularization surgery in adult moyamoya disease","volume":"45","author":"Cho WS","year":"2014","unstructured":"Cho WS, Kim JE, Kim CH,  Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke. 2014;45(10):3025\u20133031."},{"key":"b25","series-title":"World Neurosurg","first-page":"e1032","article-title":"Long-term outcomes after combined revascularization surgery in adult hemorrhagic moyamoya disease","volume":"116","author":"Jiang H","year":"2018","unstructured":"Jiang H, Yang H, Ni W,  Long-term outcomes after combined revascularization surgery in adult hemorrhagic moyamoya disease. World Neurosurg. 2018;116:e1032\u2013e1041."},{"issue":"4","key":"b26","series-title":"Neurosurg Rev","first-page":"615","article-title":"Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management","volume":"39","author":"Rashad S","year":"2016","unstructured":"Rashad S, Fujimura M, Niizuma K, Endo H, Tominaga T. Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. Neurosurg Rev. 2016;39(4):615\u2013623."},{"key":"b27","series-title":"World Neurosurg","first-page":"179","article-title":"Perioperative complications and long-term outcomes after bypasses in adults with moyamoya disease: a systematic review and meta-analysis","volume":"92","author":"Sun H","year":"2016","unstructured":"Sun H, Wilson C, Ozpinar A,  Perioperative complications and long-term outcomes after bypasses in adults with moyamoya disease: a systematic review and meta-analysis. World Neurosurg. 2016;92:179\u2013188."},{"key":"b28","series-title":"Clin Neurol Neurosurg","first-page":"106869","article-title":"Postoperative neovascularization, cerebral hemodynamics, and clinical prognosis between combined and indirect bypass revascularization procedures in hemorrhagic moyamoya disease","volume":"208","author":"Sun J","year":"2021","unstructured":"Sun J, Li ZY, Chen C, Ling C, Li H, Wang H. Postoperative neovascularization, cerebral hemodynamics, and clinical prognosis between combined and indirect bypass revascularization procedures in hemorrhagic moyamoya disease. Clin Neurol Neurosurg. 2021;208:106869."},{"issue":"5","key":"b29","series-title":"Stroke","first-page":"1130","article-title":"Clinical role of microembolic signals in adult moyamoya disease with ischemic stroke","volume":"50","author":"Jeon C","year":"2019","unstructured":"Jeon C, Yeon JY, Jo KI, Hong SC, Kim JS. Clinical role of microembolic signals in adult moyamoya disease with ischemic stroke. Stroke. 2019;50(5):1130\u20131135."},{"issue":"12","key":"b30","series-title":"N Engl J Med","first-page":"1226","article-title":"Moyamoya disease and moyamoya syndrome","volume":"360","author":"Scott RM","year":"2009","unstructured":"Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1226\u20131237."},{"issue":"3","key":"b31","series-title":"BMJ Open","first-page":"e009942","article-title":"Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study)","volume":"6","author":"Onozuka D","year":"2016","unstructured":"Onozuka D, Hagihara A, Nishimura K,  Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open. 2016;6(3):e009942."},{"issue":"1","key":"b32","series-title":"Sci Rep","first-page":"19367","article-title":"Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease","volume":"11","author":"Pang CH","year":"2021","unstructured":"Pang CH, Cho WS, Kang HS, Kim JE. Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease. Sci Rep. 2021;11(1):19367."},{"issue":"5","key":"b33","series-title":"Acta Neurochir (Wien)","first-page":"1485","article-title":"Effects of aspirin and heparin treatment on perioperative outcomes in patients with moyamoya disease","volume":"163","author":"Kanamori F","year":"2021","unstructured":"Kanamori F, Araki Y, Yokoyama K,  Effects of aspirin and heparin treatment on perioperative outcomes in patients with moyamoya disease. Acta Neurochir (Wien). 2021;163(5):1485\u20131491."},{"issue":"4","key":"b34","series-title":"Cardiovasc Drugs Ther","first-page":"777","article-title":"Cilostazol: a review of basic mechanisms and clinical uses","volume":"36","author":"Kherallah RY","year":"2022","unstructured":"Kherallah RY, Khawaja M, Olson M, Angiolillo D, Birnbaum Y. Cilostazol: a review of basic mechanisms and clinical uses. Cardiovasc Drugs Ther. 2022;36(4):777\u2013792."},{"issue":"11","key":"b35","series-title":"Stroke","first-page":"3430","article-title":"Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: subanalysis of the CSPS.com trial","volume":"52","author":"Hoshino H","year":"2021","unstructured":"Hoshino H, Toyoda K, Omae K,  Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: subanalysis of the CSPS.com trial. Stroke. 2021;52(11):3430\u20133439."},{"issue":"1","key":"b36","series-title":"Circulation","first-page":"21","article-title":"Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis","volume":"135","author":"Pan Y","year":"2017","unstructured":"Pan Y, Chen W, Xu Y,  Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135(1):21\u201333."},{"key":"b37","series-title":"StatPearls [Internet]","article-title":"Cilostazol","author":"Balinski AM","year":"2022","unstructured":"Balinski AM, Preuss CV. Cilostazol. In: StatPearls [Internet]. StatPearls Publishing; 2022."},{"issue":"3","key":"b38","series-title":"Thromb Haemost","first-page":"490","article-title":"Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity","volume":"118","author":"Alemanno L","year":"2018","unstructured":"Alemanno L, Massimi I, Klaus V,  Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity. Thromb Haemost. 2018;118(3):490\u2013501."},{"key":"b39","series-title":"Clin Interv Aging","first-page":"1271","article-title":"Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease","volume":"12","author":"Zhang JW","year":"2017","unstructured":"Zhang JW, Liu WW, McCaffrey TA,  Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. Clin Interv Aging. 2017;12:1271\u20131279."},{"issue":"5","key":"b40","series-title":"Cardiovasc Drugs Ther","first-page":"321","article-title":"The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation","volume":"21","author":"Manickavasagam S","year":"2007","unstructured":"Manickavasagam S, Ye Y, Lin Y,  The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007;21(5):321\u2013330."},{"issue":"10","key":"b41","series-title":"Arterioscler Thromb Vasc Biol","first-page":"2278","article-title":"Cilostazol suppresses angiotensin II-induced vasoconstriction via protein kinase A-mediated phosphorylation of the transient receptor potential canonical 6 channel","volume":"31","author":"Nishioka K","year":"2011","unstructured":"Nishioka K, Nishida M, Ariyoshi M,  Cilostazol suppresses angiotensin II-induced vasoconstriction via protein kinase A-mediated phosphorylation of the transient receptor potential canonical 6 channel. Arterioscler Thromb Vasc Biol. 2011;31(10):2278\u20132286."},{"issue":"4","key":"b42","series-title":"J Stroke Cerebrovasc Dis","first-page":"147","article-title":"Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh F","year":"2000","unstructured":"Gotoh F, Tohgi H, Hirai S,  Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9(4):147\u2013157."},{"issue":"10","key":"b43","series-title":"Lancet Neurol","first-page":"959","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara Y","year":"2010","unstructured":"Shinohara Y, Katayama Y, Uchiyama S,  Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959\u2013968."},{"issue":"6","key":"b44","series-title":"Lancet Neurol","first-page":"494","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study","volume":"7","author":"Huang Y","year":"2008","unstructured":"Huang Y, Cheng Y, Wu J,  Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008;7(6):494\u2013499."},{"issue":"10","key":"b45","series-title":"Neurology","first-page":"e983","article-title":"Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post hoc analysis","volume":"98","author":"Toyoda K","year":"2022","unstructured":"Toyoda K, Omae K, Hoshino H,  Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post hoc analysis. Neurology. 2022;98(10):e983\u2013e992."},{"issue":"12","key":"b46","series-title":"JAMA Neurol","first-page":"1466","article-title":"Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials","volume":"76","author":"Pan Y","year":"2019","unstructured":"Pan Y, Elm JJ, Li H,  Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials. JAMA Neurol. 2019;76(12):1466\u20131473."},{"issue":"1","key":"b47","series-title":"Cerebrovasc Dis","first-page":"65","article-title":"Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial","volume":"32","author":"Lee YS","year":"2011","unstructured":"Lee YS, Bae HJ, Kang DW,  Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011;32(1):65\u201371."},{"issue":"4","key":"b48","series-title":"J Stroke Cerebrovasc Dis","first-page":"449","article-title":"Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial","volume":"22","author":"Shimizu H","year":"2013","unstructured":"Shimizu H, Tominaga T, Ogawa A,  Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. J Stroke Cerebrovasc Dis. 2013;22(4):449\u2013456."},{"issue":"1-2","key":"b49","series-title":"J Neurol Sci","first-page":"22","article-title":"Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study","volume":"313","author":"Nakamura T","year":"2012","unstructured":"Nakamura T, Tsuruta S, Uchiyama S. Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci. 2012;313(1-2):22\u201326."},{"issue":"15","key":"b50","series-title":"J Am Heart Assoc","first-page":"e012652","article-title":"Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset","volume":"8","author":"Aoki J","year":"2019","unstructured":"Aoki J, Iguchi Y, Urabe T,  Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset. J Am Heart Assoc. 2019;8(15):e012652."},{"issue":"12","key":"b51","series-title":"J Stroke Cerebrovasc Dis","first-page":"3605","article-title":"Trends of antiplatelet therapy for the management of moyamoya disease in Japan: results of a nationwide survey","volume":"27","author":"Oki K","year":"2018","unstructured":"Oki K, Katsumata M, Izawa Y, Takahashi S, Suzuki N, Houkin K. Trends of antiplatelet therapy for the management of moyamoya disease in Japan: results of a nationwide survey. J Stroke Cerebrovasc Dis. 2018;27(12):3605\u20133612."},{"issue":"5","key":"b52","series-title":"J Am Heart Assoc","first-page":"e017701","article-title":"Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study","volume":"10","author":"Seo WK","year":"2021","unstructured":"Seo WK, Kim JY, Choi EH,  Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study. J Am Heart Assoc. 2021;10(5):e017701."},{"issue":"11","key":"b53","series-title":"J Stroke Cerebrovasc Dis","first-page":"3373","article-title":"Comparison of effects between clopidogrel and cilostazol on cerebral perfusion in nonsurgical adult patients with symptomatically ischemic moyamoya disease: subanalysis of a prospective cohort","volume":"27","author":"Chiba T","year":"2018","unstructured":"Chiba T, Setta K, Shimada Y,  Comparison of effects between clopidogrel and cilostazol on cerebral perfusion in nonsurgical adult patients with symptomatically ischemic moyamoya disease: subanalysis of a prospective cohort. J Stroke Cerebrovasc Dis. 2018;27(11):3373\u20133379."},{"issue":"5","key":"b54","series-title":"Neurol Res","first-page":"480","article-title":"Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort","volume":"41","author":"Ando S","year":"2019","unstructured":"Ando S, Tsutsui S, Miyoshi K,  Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort. Neurol Res. 2019;41(5):480\u2013487."},{"issue":"3","key":"b55","series-title":"Neurotherapeutics","first-page":"784","article-title":"Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study","volume":"14","author":"Tai SY","year":"2017","unstructured":"Tai SY, Chien CY, Chang YH, Yang YH. Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study. Neurotherapeutics. 2017;14(3):784\u2013791."},{"issue":"1","key":"b56","series-title":"J Stroke","first-page":"128","article-title":"Cilostazol and probucol for cognitive decline after stroke: a cognitive outcome substudy of the PICASSO trial","volume":"23","author":"Lim JS","year":"2021","unstructured":"Lim JS, Kwon SU, Yu KH,  Cilostazol and probucol for cognitive decline after stroke: a cognitive outcome substudy of the PICASSO trial. J Stroke. 2021;23(1):128\u2013131."},{"issue":"10","key":"b57","series-title":"Stroke","first-page":"e635","article-title":"Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities","volume":"52","author":"de Havenon A","year":"2021","unstructured":"de Havenon A, Sheth KN, Madsen TE,  Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities. Stroke. 2021;52(10):e635\u2013e645."},{"issue":"15","key":"b58","series-title":"Expert Opin Pharmacother","first-page":"1719","article-title":"Cilostazol for treatment of cerebral infarction","volume":"19","author":"Noma K","year":"2018","unstructured":"Noma K, Higashi Y. Cilostazol for treatment of cerebral infarction. Expert Opin Pharmacother. 2018;19(15):1719\u20131726."},{"issue":"20","key":"b59","series-title":"J Am Heart Assoc","first-page":"e022575","article-title":"Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis","volume":"10","author":"Uchiyama S","year":"2021","unstructured":"Uchiyama S, Toyoda K, Omae K,  Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis. J Am Heart Assoc. 2021;10(20):e022575."},{"issue":"3","key":"b60","series-title":"J Stroke Cerebrovasc Dis","first-page":"105581","article-title":"Cilostazol versus aspirin for secondary stroke prevention: systematic review and meta-analysis","volume":"30","author":"Lin MP","year":"2021","unstructured":"Lin MP, Meschia JF, Gopal N,  Cilostazol versus aspirin for secondary stroke prevention: systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(3):105581."},{"issue":"3","key":"b61","series-title":"Stroke Vasc Neurol","first-page":"410","article-title":"Cilostazol for secondary stroke prevention: systematic review and meta-analysis","volume":"6","author":"Tan CH","year":"2021","unstructured":"Tan CH, Wu AG, Sia CH,  Cilostazol for secondary stroke prevention: systematic review and meta-analysis. Stroke Vasc Neurol. 2021;6(3):410\u2013423."},{"issue":"6","key":"b62","series-title":"Lancet Neurol","first-page":"539","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda K","year":"2019","unstructured":"Toyoda K, Uchiyama S, Yamaguchi T,  Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2019;18(6):539\u2013548."},{"issue":"1","key":"b63","series-title":"Ann Pharmacother","first-page":"172","article-title":"Possible ranitidine-induced cholestatic jaundice","volume":"36","author":"Liberopoulos EN","year":"2002","unstructured":"Liberopoulos EN, Nonni AB, Tsianos EV, Elisaf MS. Possible ranitidine-induced cholestatic jaundice. Ann Pharmacother. 2002;36(1):172."},{"issue":"8","key":"b64","series-title":"Stroke","first-page":"2374","article-title":"Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis","volume":"51","author":"McHutchison C","year":"2020","unstructured":"McHutchison C, Blair GW, Appleton JP,  Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis. Stroke. 2020;51(8):2374\u20132385."},{"issue":"3","key":"b65","series-title":"Stroke","first-page":"931","article-title":"Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial","volume":"51","author":"Kim BJ","year":"2020","unstructured":"Kim BJ, Kwon SU, Park JH,  Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial. Stroke. 2020;51(3):931\u2013937."},{"issue":"12","key":"b66","series-title":"Stroke","first-page":"3503","article-title":"Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis","volume":"50","author":"Kim SM","year":"2019","unstructured":"Kim SM, Jung JM, Kim BJ, Lee JS, Kwon SU. Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis. Stroke. 2019;50(12):3503\u20133511."},{"issue":"1","key":"b1","series-title":"J Stroke","first-page":"2","article-title":"Moyamoya disease: epidemiology, clinical features, and diagnosis","volume":"18","author":"Kim JS","year":"2016","unstructured":"Kim JS. Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke. 2016;18(1):2\u201311."},{"issue":"11","key":"b2","series-title":"Int J Clin Exp Med","first-page":"21351","article-title":"Ischemic and hemorrhagic moyamoya disease in adults: CT findings","volume":"8","author":"Xie A","year":"2015","unstructured":"Xie A, Luo L, Ding Y, Li G. Ischemic and hemorrhagic moyamoya disease in adults: CT findings. Int J Clin Exp Med. 2015;8(11):21351\u201321357."},{"issue":"4","key":"b3","series-title":"Neurosurg Clin N Am","first-page":"403","article-title":"Rethinking cerebral bypass surgery","volume":"33","author":"Rennert RC","year":"2022","unstructured":"Rennert RC, Russin JJ. Rethinking cerebral bypass surgery. Neurosurg Clin N Am. 2022;33(4):403\u2013417."},{"issue":"3","key":"b4","series-title":"Int J Stroke","first-page":"246","article-title":"Etiology and pathogenesis of moyamoya disease: an update on disease prevalence","volume":"12","author":"Huang S","year":"2017","unstructured":"Huang S, Guo ZN, Shi M, Yang Y, Rao M. Etiology and pathogenesis of moyamoya disease: an update on disease prevalence. Int J Stroke. 2017;12(3):246\u2013253."},{"key":"b5","series-title":"Primer on Cerebrovascular Diseases","first-page":"561","article-title":"Moyamoya disease and syndrome","author":"Kim JS","year":"2017","unstructured":"Kim JS. Moyamoya disease and syndrome. In: Caplan LR, Biller J, Leary MC,  eds. Primer on Cerebrovascular Diseases. 2nd ed. Academic Press; 2017:561-566."},{"issue":"1","key":"b6","series-title":"J Stroke","first-page":"12","article-title":"The pathophysiology of moyamoya disease: an update","volume":"18","author":"Bang OY","year":"2016","unstructured":"Bang OY, Fujimura M, Kim SK. The pathophysiology of moyamoya disease: an update. J Stroke. 2016;18(1):12\u201320."},{"issue":"71","key":"b7","series-title":"BMJ","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM,  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71):n71."},{"issue":"5","key":"b8","series-title":"Neurol Med Chir (Tokyo)","first-page":"245","article-title":"Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis)","volume":"52","year":"2012","unstructured":"Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52(5):245\u2013266."},{"issue":"5","key":"b9","series-title":"Cerebrovasc Dis","first-page":"455","article-title":"Perfusion-weighted magnetic resonance imaging used in assessing hemodynamics following superficial temporal artery-middle cerebral artery bypass in patients with moyamoya disease","volume":"35","author":"Li Z","year":"2013","unstructured":"Li Z, Zhou P, Xiong Z,  Perfusion-weighted magnetic resonance imaging used in assessing hemodynamics following superficial temporal artery-middle cerebral artery bypass in patients with moyamoya disease. Cerebrovasc Dis. 2013;35(5):455\u2013460."},{"issue":"1","key":"b10","series-title":"Eur Radiol","first-page":"254","article-title":"CT perfusion assessment of moyamoya syndrome before and after direct revascularization (superficial temporal artery to middle cerebral artery bypass)","volume":"26","author":"Chen Y","year":"2016","unstructured":"Chen Y, Xu W, Guo X,  CT perfusion assessment of moyamoya syndrome before and after direct revascularization (superficial temporal artery to middle cerebral artery bypass). Eur Radiol. 2016;26(1):254\u2013261."},{"issue":"12","key":"b11","series-title":"Stroke","first-page":"3572","article-title":"Direct, indirect, and combined extracranial-to-intracranial bypass for adult moyamoya disease: an updated systematic review and meta-analysis","volume":"53","author":"Nguyen VN","year":"2022","unstructured":"Nguyen VN, Motiwala M, Elarjani T,  Direct, indirect, and combined extracranial-to-intracranial bypass for adult moyamoya disease: an updated systematic review and meta-analysis. Stroke. 2022;53(12):3572\u20133582."},{"key":"b12","series-title":"Front Surg","first-page":"966430","article-title":"Surgical techniques and indications for treatment of adult moyamoya disease","volume":"9","author":"Nguyen VN","year":"2022","unstructured":"Nguyen VN, Parikh KA, Motiwala M,  Surgical techniques and indications for treatment of adult moyamoya disease. Front Surg. 2022;9:966430."},{"issue":"5","key":"b13","series-title":"Neurosurg Focus","first-page":"e5","article-title":"Long-term outcome after STA-MCA anastomosis for moyamoya disease","volume":"5","author":"Miyamoto S","year":"1998","unstructured":"Miyamoto S, Akiyama Y, Nagata I,  Long-term outcome after STA-MCA anastomosis for moyamoya disease. Neurosurg Focus. 1998;5(5):e5."},{"issue":"2","key":"b14","series-title":"Neurosurg Focus","first-page":"E15","article-title":"Long-term outcome of superficial temporal artery-middle cerebral artery bypass for patients with moyamoya disease in the US","volume":"24","author":"Mesiwala AH","year":"2008","unstructured":"Mesiwala AH, Sviri G, Fatemi N, Britz GW, Newell DW. Long-term outcome of superficial temporal artery-middle cerebral artery bypass for patients with moyamoya disease in the US. Neurosurg Focus. 2008;24(2):E15."},{"issue":"5","key":"b15","series-title":"Stroke","first-page":"1415","article-title":"Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial","volume":"45","author":"Miyamoto S","year":"2014","unstructured":"Miyamoto S, Yoshimoto T, Hashimoto N,  Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke. 2014;45(5):1415\u20131421."},{"key":"b16","series-title":"World Neurosurg","first-page":"354","article-title":"Meta-analysis of prognosis of different treatments for symptomatic moyamoya disease","volume":"127","author":"Li Q","year":"2019","unstructured":"Li Q, Gao Y, Xin W,  Meta-analysis of prognosis of different treatments for symptomatic moyamoya disease. World Neurosurg. 2019;127:354\u2013361."},{"issue":"3","key":"b17","series-title":"J Neurosurg","first-page":"793","article-title":"Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults","volume":"128","author":"Jeon JP","year":"2018","unstructured":"Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW. Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg. 2018;128(3):793\u2013799."},{"issue":"4","key":"b18","series-title":"Neurosurg Focus","first-page":"E7","article-title":"Surgical management of moyamoya disease: a review","volume":"26","author":"Baaj AA","year":"2009","unstructured":"Baaj AA, Agazzi S, Sayed ZA, Toledo M, Spetzler RF, van Loveren H. Surgical management of moyamoya disease: a review. Neurosurg Focus. 2009;26(4):E7."},{"issue":"3","key":"b19","series-title":"Surg Neurol","first-page":"273","article-title":"Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease","volume":"67","author":"Fujimura M","year":"2007","unstructured":"Fujimura M, Kaneta T, Mugikura S, Shimizu H, Tominaga T. Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol. 2007;67(3):273\u2013282."},{"issue":"10","key":"b20","series-title":"Childs Nerv Syst","first-page":"734","article-title":"How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography","volume":"20","author":"Houkin K","year":"2004","unstructured":"Houkin K, Nakayama N, Kuroda S, Ishikawa T, Nonaka T. How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst. 2004;20(10):734\u2013741."},{"issue":"6","key":"b21","series-title":"Surg Neurol","first-page":"541","article-title":"Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients?","volume":"45","author":"Mizoi K","year":"1996","unstructured":"Mizoi K, Kayama T, Yoshimoto T, Nagamine Y. Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients? Surg Neurol. 1996;45(6):541\u2013549."},{"issue":"suppl 2","key":"b22","series-title":"Clin Neurol Neurosurg","first-page":"S151","article-title":"Moyamoya disease in adults: characteristics of clinical presentation and outcome after encephalo-duro-arterio-synangiosis","volume":"99","author":"Han DH","year":"1997","unstructured":"Han DH, Nam DH, Oh CW. Moyamoya disease in adults: characteristics of clinical presentation and outcome after encephalo-duro-arterio-synangiosis. Clin Neurol Neurosurg. 1997;99(suppl 2):S151\u2013S155."},{"issue":"4","key":"b23","series-title":"Neurosurg Rev","first-page":"1877","article-title":"Limits and pitfalls of indirect revascularization in moyamoya disease and syndrome","volume":"44","author":"Fiaschi P","year":"2021","unstructured":"Fiaschi P, Scala M, Piatelli G,  Limits and pitfalls of indirect revascularization in moyamoya disease and syndrome. Neurosurg Rev. 2021;44(4):1877\u20131887."},{"issue":"10","key":"b24","series-title":"Stroke","first-page":"3025","article-title":"Long-term outcomes after combined revascularization surgery in adult moyamoya disease","volume":"45","author":"Cho WS","year":"2014","unstructured":"Cho WS, Kim JE, Kim CH,  Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke. 2014;45(10):3025\u20133031."},{"key":"b25","series-title":"World Neurosurg","first-page":"e1032","article-title":"Long-term outcomes after combined revascularization surgery in adult hemorrhagic moyamoya disease","volume":"116","author":"Jiang H","year":"2018","unstructured":"Jiang H, Yang H, Ni W,  Long-term outcomes after combined revascularization surgery in adult hemorrhagic moyamoya disease. World Neurosurg. 2018;116:e1032\u2013e1041."},{"issue":"4","key":"b26","series-title":"Neurosurg Rev","first-page":"615","article-title":"Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management","volume":"39","author":"Rashad S","year":"2016","unstructured":"Rashad S, Fujimura M, Niizuma K, Endo H, Tominaga T. Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. Neurosurg Rev. 2016;39(4):615\u2013623."},{"key":"b27","series-title":"World Neurosurg","first-page":"179","article-title":"Perioperative complications and long-term outcomes after bypasses in adults with moyamoya disease: a systematic review and meta-analysis","volume":"92","author":"Sun H","year":"2016","unstructured":"Sun H, Wilson C, Ozpinar A,  Perioperative complications and long-term outcomes after bypasses in adults with moyamoya disease: a systematic review and meta-analysis. World Neurosurg. 2016;92:179\u2013188."},{"key":"b28","series-title":"Clin Neurol Neurosurg","first-page":"106869","article-title":"Postoperative neovascularization, cerebral hemodynamics, and clinical prognosis between combined and indirect bypass revascularization procedures in hemorrhagic moyamoya disease","volume":"208","author":"Sun J","year":"2021","unstructured":"Sun J, Li ZY, Chen C, Ling C, Li H, Wang H. Postoperative neovascularization, cerebral hemodynamics, and clinical prognosis between combined and indirect bypass revascularization procedures in hemorrhagic moyamoya disease. Clin Neurol Neurosurg. 2021;208:106869."},{"issue":"5","key":"b29","series-title":"Stroke","first-page":"1130","article-title":"Clinical role of microembolic signals in adult moyamoya disease with ischemic stroke","volume":"50","author":"Jeon C","year":"2019","unstructured":"Jeon C, Yeon JY, Jo KI, Hong SC, Kim JS. Clinical role of microembolic signals in adult moyamoya disease with ischemic stroke. Stroke. 2019;50(5):1130\u20131135."},{"issue":"12","key":"b30","series-title":"N Engl J Med","first-page":"1226","article-title":"Moyamoya disease and moyamoya syndrome","volume":"360","author":"Scott RM","year":"2009","unstructured":"Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1226\u20131237."},{"issue":"3","key":"b31","series-title":"BMJ Open","first-page":"e009942","article-title":"Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study)","volume":"6","author":"Onozuka D","year":"2016","unstructured":"Onozuka D, Hagihara A, Nishimura K,  Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open. 2016;6(3):e009942."},{"issue":"1","key":"b32","series-title":"Sci Rep","first-page":"19367","article-title":"Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease","volume":"11","author":"Pang CH","year":"2021","unstructured":"Pang CH, Cho WS, Kang HS, Kim JE. Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease. Sci Rep. 2021;11(1):19367."},{"issue":"5","key":"b33","series-title":"Acta Neurochir (Wien)","first-page":"1485","article-title":"Effects of aspirin and heparin treatment on perioperative outcomes in patients with moyamoya disease","volume":"163","author":"Kanamori F","year":"2021","unstructured":"Kanamori F, Araki Y, Yokoyama K,  Effects of aspirin and heparin treatment on perioperative outcomes in patients with moyamoya disease. Acta Neurochir (Wien). 2021;163(5):1485\u20131491."},{"issue":"4","key":"b34","series-title":"Cardiovasc Drugs Ther","first-page":"777","article-title":"Cilostazol: a review of basic mechanisms and clinical uses","volume":"36","author":"Kherallah RY","year":"2022","unstructured":"Kherallah RY, Khawaja M, Olson M, Angiolillo D, Birnbaum Y. Cilostazol: a review of basic mechanisms and clinical uses. Cardiovasc Drugs Ther. 2022;36(4):777\u2013792."},{"issue":"11","key":"b35","series-title":"Stroke","first-page":"3430","article-title":"Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: subanalysis of the CSPS.com trial","volume":"52","author":"Hoshino H","year":"2021","unstructured":"Hoshino H, Toyoda K, Omae K,  Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: subanalysis of the CSPS.com trial. Stroke. 2021;52(11):3430\u20133439."},{"issue":"1","key":"b36","series-title":"Circulation","first-page":"21","article-title":"Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis","volume":"135","author":"Pan Y","year":"2017","unstructured":"Pan Y, Chen W, Xu Y,  Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135(1):21\u201333."},{"key":"b37","series-title":"StatPearls [Internet]","article-title":"Cilostazol","author":"Balinski AM","year":"2022","unstructured":"Balinski AM, Preuss CV. Cilostazol. In: StatPearls [Internet]. StatPearls Publishing; 2022."},{"issue":"3","key":"b38","series-title":"Thromb Haemost","first-page":"490","article-title":"Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity","volume":"118","author":"Alemanno L","year":"2018","unstructured":"Alemanno L, Massimi I, Klaus V,  Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity. Thromb Haemost. 2018;118(3):490\u2013501."},{"key":"b39","series-title":"Clin Interv Aging","first-page":"1271","article-title":"Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease","volume":"12","author":"Zhang JW","year":"2017","unstructured":"Zhang JW, Liu WW, McCaffrey TA,  Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. Clin Interv Aging. 2017;12:1271\u20131279."},{"issue":"5","key":"b40","series-title":"Cardiovasc Drugs Ther","first-page":"321","article-title":"The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation","volume":"21","author":"Manickavasagam S","year":"2007","unstructured":"Manickavasagam S, Ye Y, Lin Y,  The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007;21(5):321\u2013330."},{"issue":"10","key":"b41","series-title":"Arterioscler Thromb Vasc Biol","first-page":"2278","article-title":"Cilostazol suppresses angiotensin II-induced vasoconstriction via protein kinase A-mediated phosphorylation of the transient receptor potential canonical 6 channel","volume":"31","author":"Nishioka K","year":"2011","unstructured":"Nishioka K, Nishida M, Ariyoshi M,  Cilostazol suppresses angiotensin II-induced vasoconstriction via protein kinase A-mediated phosphorylation of the transient receptor potential canonical 6 channel. Arterioscler Thromb Vasc Biol. 2011;31(10):2278\u20132286."},{"issue":"4","key":"b42","series-title":"J Stroke Cerebrovasc Dis","first-page":"147","article-title":"Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh F","year":"2000","unstructured":"Gotoh F, Tohgi H, Hirai S,  Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9(4):147\u2013157."},{"issue":"10","key":"b43","series-title":"Lancet Neurol","first-page":"959","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara Y","year":"2010","unstructured":"Shinohara Y, Katayama Y, Uchiyama S,  Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959\u2013968."},{"issue":"6","key":"b44","series-title":"Lancet Neurol","first-page":"494","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study","volume":"7","author":"Huang Y","year":"2008","unstructured":"Huang Y, Cheng Y, Wu J,  Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008;7(6):494\u2013499."},{"issue":"10","key":"b45","series-title":"Neurology","first-page":"e983","article-title":"Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post hoc analysis","volume":"98","author":"Toyoda K","year":"2022","unstructured":"Toyoda K, Omae K, Hoshino H,  Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post hoc analysis. Neurology. 2022;98(10):e983\u2013e992."},{"issue":"12","key":"b46","series-title":"JAMA Neurol","first-page":"1466","article-title":"Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials","volume":"76","author":"Pan Y","year":"2019","unstructured":"Pan Y, Elm JJ, Li H,  Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials. JAMA Neurol. 2019;76(12):1466\u20131473."},{"issue":"1","key":"b47","series-title":"Cerebrovasc Dis","first-page":"65","article-title":"Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial","volume":"32","author":"Lee YS","year":"2011","unstructured":"Lee YS, Bae HJ, Kang DW,  Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011;32(1):65\u201371."},{"issue":"4","key":"b48","series-title":"J Stroke Cerebrovasc Dis","first-page":"449","article-title":"Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial","volume":"22","author":"Shimizu H","year":"2013","unstructured":"Shimizu H, Tominaga T, Ogawa A,  Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. J Stroke Cerebrovasc Dis. 2013;22(4):449\u2013456."},{"issue":"1-2","key":"b49","series-title":"J Neurol Sci","first-page":"22","article-title":"Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study","volume":"313","author":"Nakamura T","year":"2012","unstructured":"Nakamura T, Tsuruta S, Uchiyama S. Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci. 2012;313(1-2):22\u201326."},{"issue":"15","key":"b50","series-title":"J Am Heart Assoc","first-page":"e012652","article-title":"Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset","volume":"8","author":"Aoki J","year":"2019","unstructured":"Aoki J, Iguchi Y, Urabe T,  Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset. J Am Heart Assoc. 2019;8(15):e012652."},{"issue":"12","key":"b51","series-title":"J Stroke Cerebrovasc Dis","first-page":"3605","article-title":"Trends of antiplatelet therapy for the management of moyamoya disease in Japan: results of a nationwide survey","volume":"27","author":"Oki K","year":"2018","unstructured":"Oki K, Katsumata M, Izawa Y, Takahashi S, Suzuki N, Houkin K. Trends of antiplatelet therapy for the management of moyamoya disease in Japan: results of a nationwide survey. J Stroke Cerebrovasc Dis. 2018;27(12):3605\u20133612."},{"issue":"5","key":"b52","series-title":"J Am Heart Assoc","first-page":"e017701","article-title":"Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study","volume":"10","author":"Seo WK","year":"2021","unstructured":"Seo WK, Kim JY, Choi EH,  Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study. J Am Heart Assoc. 2021;10(5):e017701."},{"issue":"11","key":"b53","series-title":"J Stroke Cerebrovasc Dis","first-page":"3373","article-title":"Comparison of effects between clopidogrel and cilostazol on cerebral perfusion in nonsurgical adult patients with symptomatically ischemic moyamoya disease: subanalysis of a prospective cohort","volume":"27","author":"Chiba T","year":"2018","unstructured":"Chiba T, Setta K, Shimada Y,  Comparison of effects between clopidogrel and cilostazol on cerebral perfusion in nonsurgical adult patients with symptomatically ischemic moyamoya disease: subanalysis of a prospective cohort. J Stroke Cerebrovasc Dis. 2018;27(11):3373\u20133379."},{"issue":"5","key":"b54","series-title":"Neurol Res","first-page":"480","article-title":"Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort","volume":"41","author":"Ando S","year":"2019","unstructured":"Ando S, Tsutsui S, Miyoshi K,  Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort. Neurol Res. 2019;41(5):480\u2013487."},{"issue":"3","key":"b55","series-title":"Neurotherapeutics","first-page":"784","article-title":"Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study","volume":"14","author":"Tai SY","year":"2017","unstructured":"Tai SY, Chien CY, Chang YH, Yang YH. Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study. Neurotherapeutics. 2017;14(3):784\u2013791."},{"issue":"1","key":"b56","series-title":"J Stroke","first-page":"128","article-title":"Cilostazol and probucol for cognitive decline after stroke: a cognitive outcome substudy of the PICASSO trial","volume":"23","author":"Lim JS","year":"2021","unstructured":"Lim JS, Kwon SU, Yu KH,  Cilostazol and probucol for cognitive decline after stroke: a cognitive outcome substudy of the PICASSO trial. J Stroke. 2021;23(1):128\u2013131."},{"issue":"10","key":"b57","series-title":"Stroke","first-page":"e635","article-title":"Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities","volume":"52","author":"de Havenon A","year":"2021","unstructured":"de Havenon A, Sheth KN, Madsen TE,  Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities. Stroke. 2021;52(10):e635\u2013e645."},{"issue":"15","key":"b58","series-title":"Expert Opin Pharmacother","first-page":"1719","article-title":"Cilostazol for treatment of cerebral infarction","volume":"19","author":"Noma K","year":"2018","unstructured":"Noma K, Higashi Y. Cilostazol for treatment of cerebral infarction. Expert Opin Pharmacother. 2018;19(15):1719\u20131726."},{"issue":"20","key":"b59","series-title":"J Am Heart Assoc","first-page":"e022575","article-title":"Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis","volume":"10","author":"Uchiyama S","year":"2021","unstructured":"Uchiyama S, Toyoda K, Omae K,  Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis. J Am Heart Assoc. 2021;10(20):e022575."},{"issue":"3","key":"b60","series-title":"J Stroke Cerebrovasc Dis","first-page":"105581","article-title":"Cilostazol versus aspirin for secondary stroke prevention: systematic review and meta-analysis","volume":"30","author":"Lin MP","year":"2021","unstructured":"Lin MP, Meschia JF, Gopal N,  Cilostazol versus aspirin for secondary stroke prevention: systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(3):105581."},{"issue":"3","key":"b61","series-title":"Stroke Vasc Neurol","first-page":"410","article-title":"Cilostazol for secondary stroke prevention: systematic review and meta-analysis","volume":"6","author":"Tan CH","year":"2021","unstructured":"Tan CH, Wu AG, Sia CH,  Cilostazol for secondary stroke prevention: systematic review and meta-analysis. Stroke Vasc Neurol. 2021;6(3):410\u2013423."},{"issue":"6","key":"b62","series-title":"Lancet Neurol","first-page":"539","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda K","year":"2019","unstructured":"Toyoda K, Uchiyama S, Yamaguchi T,  Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2019;18(6):539\u2013548."},{"issue":"1","key":"b63","series-title":"Ann Pharmacother","first-page":"172","article-title":"Possible ranitidine-induced cholestatic jaundice","volume":"36","author":"Liberopoulos EN","year":"2002","unstructured":"Liberopoulos EN, Nonni AB, Tsianos EV, Elisaf MS. Possible ranitidine-induced cholestatic jaundice. Ann Pharmacother. 2002;36(1):172."},{"issue":"8","key":"b64","series-title":"Stroke","first-page":"2374","article-title":"Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis","volume":"51","author":"McHutchison C","year":"2020","unstructured":"McHutchison C, Blair GW, Appleton JP,  Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis. Stroke. 2020;51(8):2374\u20132385."},{"issue":"3","key":"b65","series-title":"Stroke","first-page":"931","article-title":"Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial","volume":"51","author":"Kim BJ","year":"2020","unstructured":"Kim BJ, Kwon SU, Park JH,  Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial. Stroke. 2020;51(3):931\u2013937."},{"issue":"12","key":"b66","series-title":"Stroke","first-page":"3503","article-title":"Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis","volume":"50","author":"Kim SM","year":"2019","unstructured":"Kim SM, Jung JM, Kim BJ, Lee JS, Kwon SU. Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis. Stroke. 2019;50(12):3503\u20133511."}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/55\/4\/article-pE9.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/55\/4\/article-pE9.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/55\/4\/article-pE9.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:24:00Z","timestamp":1779524640000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/55\/4\/article-pE9.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":132,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/2023.7.focus23327","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}